

Silvia Piantoni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7618447/silvia-piantoni-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

824
citations

15
h-index

28
g-index

56
ext. papers

1,118
ext. citations

4.5
avg, IF

4.14
L-index

#	Paper	IF	Citations
44	A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.. <i>Clinical Reviews in Allergy and Immunology</i> , 2022 , 1	12.3	0
43	Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.. <i>Frontiers in Medicine</i> , 2022 , 9, 849086	4.9	1
42	Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.. <i>Human Vaccines and Immunotherapeutics</i> , 2022 , 2072143	4.4	1
41	The Influence of Treatment of Inflammatory Arthritis During Pregnancy on the Long-Term Children's Outcome. <i>Frontiers in Pharmacology</i> , 2021 , 12, 626258	5.6	0
40	Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. <i>Frontiers in Pharmacology</i> , 2021 , 12, 666971	5.6	0
39	Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. <i>Blood Reviews</i> , 2021 , 46, 100745	11.1	60
38	Response to: Correspondence on Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome by Kawada. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	7
37	Improvement of lupus-associated fatigue with modafinil: Report of two cases. <i>Lupus</i> , 2021 , 30, 1013-1016	16	
36	Reports of three long-term lung disease following SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021 , 93, 2585-2587	19.7	
35	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 91-97	2.2	1
34	Reply to: Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis by Castellanos-Moreira et al. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 1144 ^{2.2}	2.2	2
33	Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 91-97	2.2	2
32	Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease. <i>Rheumatology</i> , 2020 , 59, 1769-1770	3.9	14
31	The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhuriyet M et al. <i>Clinical Rheumatology</i> , 2020 , 39, 2489-2490	3.9	10
30	Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases. <i>Nutrients</i> , 2020 , 12,	6.7	20
29	Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome 2020 ,		8
28	Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences?. <i>European Journal of Internal Medicine</i> , 2020 , 73, 76-82	3.9	2

27	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020 , 11, 572876	8.4	4
26	COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. <i>Lancet Rheumatology</i> , 2020 , 2, e549-e556	14.2	75
25	Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1286-1289	2.4	82
24	Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: Colchicine treatment in community healthcare setting to prevent severe COVID-19 by Della-Torre. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
23	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020 , 11, 584241	8.4	86
22	Is cholecalciferol a potential disease-modifying anti-rheumatic drug for the management of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 343-349	2.2	2
21	Association Between Changes in BlyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab. <i>Frontiers in Pharmacology</i> , 2019 , 10, 433	5.6	15
20	Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors. <i>Lupus</i> , 2019 , 28, 210-216	2.6	10
19	Decreased circulating T regulatory lymphocytes in obese patients undergoing bariatric surgery. <i>PLoS ONE</i> , 2018 , 13, e0197178	3.7	12
18	Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1218-1227	4.7	4
17	Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes. <i>Lupus</i> , 2018 , 27, 143-149	2.6	16
16	Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 685	2.2	3
15	Relationship between different subpopulations of circulating CD4+ T lymphocytes and microvascular or systemic oxidative stress in humans. <i>Blood Pressure</i> , 2017 , 26, 237-245	1.7	10
14	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. <i>Rheumatology</i> , 2017 , 56, 1874-1883	3.9	7
13	Relationship Between Different Subpopulations of Circulating CD4+ T-lymphocytes and Microvascular Structural Alterations in Humans. <i>American Journal of Hypertension</i> , 2017 , 30, 51-60	2.3	18
12	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017 , 69, 115-123	4.7	74
11	Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016 , 35, 1065-9	3.9	4
10	Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. <i>Lupus</i> , 2015 , 24, 490-8	2.6	42

9	A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. <i>Lupus</i> , 2015 , 24, 499-506	2.6	47
8	CD8+ T cell profiles in patients with rheumatoid arthritis-the effects of costimulation blockade: comment on the article by Carvalheiro et al. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2273-4	9.5	2
7	Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. <i>Rheumatology International</i> , 2015 , 35, 1571-3	3.6	17
6	Winter lupus flares are associated with low vitamin D levels in a retrospective longitudinal study of Italian adult patients. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 153-8	2.2	9
5	Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 666-72	4.1	51
4	Topoisomerase I (SCL 70) Autoantibodies 2014 , 239-245		
3	Clinical significance of IgA anti-cardiolipin and IgA anti- β glycoprotein I antibodies. <i>Current Rheumatology Reports</i> , 2013 , 15, 343	4.9	39
2	Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. <i>Reumatismo</i> , 2012 , 64, 307-13	1.1	22
1	Vitamin D and antiphospholipid syndrome. <i>Lupus</i> , 2012 , 21, 736-40	2.6	41